Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes † Highlights • Consistent decrease over two decades in ischemic stroke rates among US Medicare atrial fibrillation patients with and without diabetes.
Introduction
The global burdens of diabetes mellitus and atrial fibrillation (AF) are increasing progressively. The prevalence of diabetes in the US was approximately 29 million in 2014. 1 The prevalence of AF was estimated at approximately 5 million in 2010 and projected to increase to approximately 12 million by 2030. 2 As a corollary, these conditions are becoming increasingly coprevalent; in a randomized controlled trial involving 11 140 patients with type 2 diabetes, approximately 7.6% were diagnosed with AF. 3 Moreover, patients with newly diagnosed diabetes have significantly higher incidence rates of newly diagnosed AF than patients without diabetes. 4 Data from the Framingham Heart Study showed an increase in the age-and sex-adjusted prevalence of diabetes among AF patients from 5.7% in the 1958-67 cohort to 19 .6% in the 1998-2007 cohort. 5 The population attributable risk of diabetes for development of incident AF has also increased steadily over the past 50 years. 5 The combination of diabetes and AF confers a 61% higher hazard of adjusted all-cause mortality relative to patients without AF, and a substantially increased hazard of cardiovascular mortality, stroke, and heart failure. 3, 4 Diabetes is well recognized as an important risk factor for the prediction of future ischemic stroke among patients with non-valvular AF (NVAF). In various cohorts of patients with NVAF, diabetes has been consistently identified in multivariate analyses as an independent and significant risk factor for stroke. 6, 7 In a study comparing all proposed risk stratification schemes for predicting ischemic stroke risk in NVAF patients, diabetes featured as a significant variable in 10 of 12 schemes. 8 The most recent societal guidelines for managing NVAF in the US endorse CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age >75 years, diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category) as the preferred classification schema for predicting ischemic stroke risk in NVAF patients (Class I recommendation), 9 with 1 point ascribed to the presence of diabetes.
The temporal reduction in rates of ischemic stroke and coincident increases in the proportion of patients receiving anticoagulation with warfarin have been well described in the general US Medicare population 10, 11 and among various demographic and ethnic subgroups. 12 Data from the Framingham Heart Study spanning five decades show a 74% reduction in stroke and a 25% reduction in mortality in 1998-2007 relative to 1958-67. 5 However, although diabetes is well established as an independent risk factor for stroke among NVAF patients, trends in ischemic stroke among diabetic patients and the proportion of diabetic patients who receive therapeutic anticoagulation in the contemporary era are unknown. In light of the enormous epidemiological burden of AF and diabetes, coprevalent AF and diabetes has serious public health implications. The aim of the present study was to compare trends in ischemic stroke rates among NVAF patients with and without diabetes to determine how well guideline-based recommendations for the use of anticoagulation have permeated into the Medicare population.
Methods
This study was performed using the Medicare 5% database, a rolling replacement cohort, with methodology similar to methodology described previously. 10, 11 Oneyear cohorts of Medicare beneficiaries (patients aged older than 65 years, excluding end-stage renal disease patients) were created from 1992 through 2010. The analysis was intentionally truncated at 2010 to avoid confounding of the data by newer oral anticoagulants. Patients with Medicare as the primary payer with at least one Medicare Part A inpatient or two Part B/outpatient claims and with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic code for AF or flutter (427.3x) were identified. Patients with valvular disease, defined as inpatient/outpatient/Part B ICD-9-CM diagnostic codes for valvular disease or procedure codes for valvular surgery were excluded (see Table S1 , available as Supplementary Material to this paper).
Comorbid conditions were identified in a similar manner using ICD-9-CM codes (Table S2 ). Of note, strokes were identified from inpatient claims when stroke was coded as the principal diagnosis (ICD-9-CM codes 434. x, 436.x for ischemic stroke; 430.x, 431.x for hemorrhagic stroke). Diabetes was identified by one Part A (institutional/inpatient) or two Part B (outpatient/ provider) claims with any of the following ICD-9-CM codes: 250.x, 357.2, 362.0x, 366.41. 13 Because warfarin prescription use cannot be directly discerned from older claims data, a previously validated 10 surrogate method for identifying warfarin use (three or more prothrombin time claims during the year after AF diagnosis) was used. All patients with two or fewer prothrombin time claims in the year after AF diagnosis were considered warfarin non-treated. Finally, in order to calculate ischemic stroke rates among warfarin-treated and -nontreated patients with diabetes, a secondary analysis was performed to calculate ischemic stroke rates in warfarin-treated AF patients after warfarin initiation. In this analysis, the time at risk between AF diagnosis and start of warfarin therapy was excluded. Rates of ischemic stroke for warfarin-treated AF patients were compared with those for warfarin-non-treated AF patients. Patient characteristics were compared using the Chi-squared test.
Results

Demographics and comorbid conditions
Demographic characteristics of this study population are presented in Table 1 . Among Medicare patients with NVAF, the proportion identified with diabetes increased from 1992 (n = 8010; 19.8%) to 2010 (n = 25 833; 32.1%).
In the overall population, several pertinent demographic changes occurred. A proportional increase in patients aged ≥85 years occurred from 1992 to 2010 (from 20% to 25%). The proportion of diabetic patients in this age group also increased (from 14% to 20%); this age group showed the highest proportional increase in diabetes over the study duration. A corresponding proportional decrease in patients aged 65-74 years occurred from 1992 to 2010 (from 37% to 32%), with a corresponding decrease in the proportion of diabetic patients (from 43% to 36%). The proportion of male patients increased from 45% to 49%, with a proportional increase in male patients with diabetes (from 44% to 52%). Diabetes increased proportionally among patients of other race (from 2.4% to 4.3%) and decreased proportionally among White patients (from 91.7% to 89.7%).
A proportional and statistically significant increase in several comorbid conditions among Medicare patients with NVAF occurred during the study period. There was a notable increase from 1992 to 2010 in the proportion of diabetic patients with chronic kidney disease (from 8% to 27%; P < 0.0001), hypertension (from 57.7% to 89.4%; P < 0.0001), and peripheral vascular disease (from 22.5% to 28.1%; P < 0.001). Conversely, there were proportional decreases in diagnostic codes for atherosclerotic coronary heart disease (from 53.5% to 50.9%; P < 0.001) and congestive heart failure (from 48.5% to 39.1%; P < 0.001). These trends may also reflect evolving definitions of these conditions over the almost two-decade-long study period.
Ischemic stroke rates and proportions receiving warfarin for therapeutic anticoagulation
Among Medicare patients with NVAF, ischemic stroke rates were significantly higher for those with than for those without diabetes throughout the study period (Figs 1, 2 ). Among patients with diabetes, ischemic stroke rates decreased steadily by 71% from 65 to 19 per 1000 patient-years from 1992 to 2010. During this period, warfarin use increased steadily from 28% to 62% (Fig. 1a) . Among patients without diabetes, ischemic stroke rates decreased by 68% from 44 to 14 per 1000 patient-years from 1992 to 2010 and warfarin use increased from 26% to 59% (Fig. 1b) . Approximately 38% of patients with diabetes did not receive anticoagulation with warfarin in 2010, compared with approximately 42% of patients without diabetes (Fig. 1a,b ).
Ischemic stroke rates among warfarin-treated and -nontreated patients
In a secondary analysis, we calculated ischemic stroke rates for warfarin-treated AF patients after warfarin initiation and compared them with rates for warfarin-non-treated patients. The ischemic stroke rates using this method were lower than rates in the primary analysis because strokes that occurred between the diagnosis of AF and the start of warfarin therapy were excluded (as was the time at risk between AF diagnosis and start of therapy) to allow accurate identification of warfarin initiation relative to the diagnosis of AF. As expected, the ischemic stroke rate decreased substantially in warfarin-treated patients with diabetes from 1992 to 2009 (from 44 to 11 per 1000 patient-years; Fig. 2a) . Importantly, the ischemic stroke rate (although higher than in warfarin-treated patients) also decreased in warfarinnon-treated patients with diabetes over the same period (from 46 to 21 per 1000 patient-years), likely reflecting improved background cardiovascular care. Ischemic stroke rates were significantly lower among non-diabetic than diabetic patients with AF. However, among non-diabetic patients also, ischemic stroke rates decreased from 1992 to 2009 among warfarin-treated patients (from 25 to 8 per 1000 patient-years) and were lower than among warfarinnon-treated patients (from 34 to 16 per 1000 patientyears; Fig. 2b ).
Discussion
Observations from the present epidemiological study indicate that temporal trends demonstrating reduced ischemic stroke rates over the past two decades among patients with NVAF give reason for optimism and are concordant among Medicare beneficiaries with and without diabetes. Noticeably higher ischemic stroke rates among diabetic patients (albeit decreasing over time) support the importance of including diabetes as a major risk factor in risk calculation models for predicting future stroke risk in the context of NVAF. However, it is worrisome that approximately 38% of Medicare beneficiaries with diabetes were not receiving anticoagulation therapy in 2010, delineating a high-risk group that deserves focused attention from the clinical community. Diabetes and AF share a complex relationship with bidirectional risk of higher incidence and adverse outcomes. Diabetes has been shown to represent an independent risk factor that is strongly associated with the development of incident AF.
14, 15 Several mechanisms have been proposed to explain the higher risk of incident AF in patients with diabetes, including autonomic dysregulation (formation of advanced glycation endproducts [AGEs], oxidative stress, free radicals, activated ribosylation), electrical and structural remodeling (myocardial lipotoxicity, cellular apoptosis, fibrosis, mitochondrial dysfunction), and insulin resistance. 16 The combination of diabetes and AF creates a significantly higher hazard of adjusted all-cause mortality, cardiovascular mortality, and heart failure, and increases the risk of thromboembolic complications, including stroke, compared with diabetes without AF. 3 Again, multiple mechanisms have been proposed for a heightened prothrombotic milieu in the context of diabetes and AF, 17 such as elevated procoagulant factors, including soluble tissue factor, induction of tissue factor mRNA expression by AGEs, elevated plasma viscosity, and enhanced platelet activation and aggregation. The Stroke Reduction in Atrial Fibrillation Working Group evaluated six independent cohorts from seven studies and reported that diabetes was a strong independent and consistent risk predictor of stroke among patients with NVAF (relative risk 1.7; 95% confidence interval [CI] 1.4-2.0). 6 Similarly, in a longitudinal community cohort study evaluating validated thromboembolic risk variables in NVAF, diabetes was identified in multivariate analysis as an independent risk factor for stroke (hazard ratio 1.58; 95% CI 1.23-2.02). 7 The annualized risk of stroke in diabetes patients ranges between 3.6% and 8.6% per year. 6 Our observational analysis confirms the higher ischemic stroke rates among Medicare diabetic relative to non-diabetic patients, supporting the notion of this population being considered high risk.
To the best of our knowledge, the present study is the first to compare trends in ischemic stroke rates among diabetic and non-diabetic patients with NVAF. It is therefore of note that although the baseline ischemic stroke rates were significantly higher among diabetic patients, the reduction in these rates over 18 years was comparable in diabetic and non-diabetic patients (71% and 68%, respectively). This likely indicates that the magnitude of benefit in stroke reduction due to various factors in that time period (anticoagulation and preventive methods) was similar. The percentage of the population receiving warfarin was also similar among diabetic and non-diabetic patients (62% and 59%, respectively, in 2010), suggesting that non-diabetic patients likely had other risk factors (older age, hypertension, congestive heart failure, stroke etc.) that prompted initiation of anticoagulation with warfarin.
It is somewhat puzzling and bothersome that a significant proportion of Medicare patients with AF and diabetes were not receiving anticoagulation with warfarin as of 2010. Medicare patients (aged >65 years) with diabetes meet contemporary guideline-recommended criteria for treatment with therapeutic anticoagulation due to a CHA 2 DS 2 -VASc score of at least 2 (diabetes and age >65 years). Moreover, in 2010, approximately 51% of the Medicare population was female and approximately 43% was aged >75 years; both these variables further increase the thromboembolic risk in the context of NVAF. Of interest, this proportion of nonanticoagulated patients is similar to the proportion of general Medicare patients previously reported not to be receiving therapeutic anticoagulation, 11, 18 but somewhat higher than the proportion reported by the Get With Guidelines Stroke Hospitals. 19 The reasons underlying the lack of therapeutic anticoagulation in more than one-third of this elderly population merit further evaluation. This proportion most likely represents patients who were deemed to have absolute or relative contraindications to anticoagulation because of actual or perceived increase in bleeding risk. It likely also includes patients who found using warfarin difficult because of lack of accessible point-of-care International Normalized Ratio (INR) testing or because of adverse drug interactions. In addition, it is unclear whether these patients were receiving any alternative antithrombotic or antiplatelet agents, which could have potentially increased their risk of bleeding on warfarin. Given the high prevalence in diabetic patients of atherosclerotic heart disease (51% in 2010) and peripheral vascular disease (28% in 2010), they were likely receiving at least one and possibly two antiplatelet agents. Conceivably, in the context of baseline antiplatelet agent use, clinicians may determine that the risk of bleeding complications with additional use of warfarin outweighs the risk of ischemic complications. We recommend that this non-anticoagulated population be a focus of future research endeavors to accurately understand these patients, identify reasons for lack of anticoagulation, and determine whether the proportion decreases in the future with the advent of newer anticoagulant agents.
Finally, the demonstration of reduced ischemic stroke rates in Medicare diabetes patients with AF who do and do not receive therapeutic anticoagulation ( Fig. 2A) is unique to the literature and extremely pertinent in this era of increasingly heightened emphasis on newer anticoagulants for AF. The trends toward reduced ischemic stroke rates (including among non-anticoagulated patients) are concordant with prior reports in the general Medicare population and similar reports using population health data. 12, 20 This is probably indicative of improved background risk factor control for the prevention of stroke, such as improved management of diabetes and other contributory risk factors, including hypertension, dyslipidemia, and smoking. 21 These trends also bring to attention the population attributable risks of AF relative to other risk factors in the occurrence of ischemic stroke in this elderly population. 22 This observation serves to remind clinicians of the importance of effective control of other modifiable factors that may contribute to non-cardioembolic mechanisms (in addition to therapeutic anticoagulation) for reducing stroke among diabetes patients with AF.
The limitations of the present observational analysis should be noted. Although temporal trends in warfarin use can be determined from this study, we are unable to report information pertaining to the quality of anticoagulation during warfarin therapy (i.e. the time in therapeutic range). Similarly, information about the duration and control of diabetes and any resultant effects on ischemic stroke rates is not available from this study cohort, but may be pertinent based on emerging evidence. 23 Importantly, among patients who sustained an ischemic stroke, it is not feasible to determine from the present analysis whether warfarin therapy began before or after the stroke. We referred to the risk calculator CHA 2 DS 2 -VASc because it is the currently recommended risk score, but it was introduced in the US during the study data collection period; the CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke [doubled]) score was the predominant guideline-directed risk assessment tool during most of the study period.
In summary, ischemic stroke rates among AF patients with and without diabetes have decreased consistently over the past two decades. This observation is coincident with increased warfarin use, but the decrease also occurred among patients who did not receive therapeutic anticoagulation with warfarin. Importantly, a significant proportion of US Medicare AF patients with diabetes did not receive anticoagulation with warfarin in 2010. It remains to be seen whether newer anticoagulant agents result in a decrease in the non-anticoagulated AF population in the future and, importantly, whether that results in a further reduction in ischemic stroke rates. Table S1 . International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis and procedure codes used to exclude patients from the atrial fibrillation analysis Table S2 . International Classification of Diseases, Ninth Revision, Clinical Modification codes used to identify comorbid conditions
